{"id":33041,"date":"2025-05-08T21:00:27","date_gmt":"2025-05-08T13:00:27","guid":{"rendered":"https:\/\/flcube.com\/?p=33041"},"modified":"2025-05-08T21:00:28","modified_gmt":"2025-05-08T13:00:28","slug":"guangzhou-regenverse-therapeutics-raises-rmb-100-million-in-pre-series-a-financing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33041","title":{"rendered":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing"},"content":{"rendered":"\n<p>China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson&#8217;s disease.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>Founded in 2019, Regenverse Therapeutics is focused on developing iPSC-derived universal off-the-shelf cell therapies for the treatment of tumors and nervous system diseases. The company boasts advanced technologies in iPSC reprogramming and cell banking, immune cell and neural cell differentiation, and gene modification to construct engineered iPS cell lines.<\/p>\n\n\n\n<p><strong>Pipeline Development<\/strong><br>Regenverse Therapeutics is also developing iNK001, an iPSC-derived natural killer cell therapy, and a program targeting Huntington&#8217;s disease. The funding will support the advancement of these innovative therapies, positioning the company at the forefront of iPSC-based treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33044,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,77,20,4054,4055],"class_list":["post-33041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-cell-therapy","tag-finance","tag-regen-therapeutics","tag-regenverse-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson&#039;s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33041\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing\" \/>\n<meta property=\"og:description\" content=\"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson&#039;s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33041\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T13:00:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T13:00:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing\",\"datePublished\":\"2025-05-08T13:00:27+00:00\",\"dateModified\":\"2025-05-08T13:00:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041\"},\"wordCount\":176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0802-1.webp\",\"keywords\":[\"Biotech\",\"Cell-therapy\",\"Finance\",\"Regen Therapeutics\",\"Regenverse Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33041#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33041\",\"name\":\"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0802-1.webp\",\"datePublished\":\"2025-05-08T13:00:27+00:00\",\"dateModified\":\"2025-05-08T13:00:28+00:00\",\"description\":\"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson's disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33041\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0802-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0802-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guangzhou Regen Therapeutics Raises RMB 100 Million in Pre-Series A Financing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33041#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson's disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33041","og_locale":"en_US","og_type":"article","og_title":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing","og_description":"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson's disease.","og_url":"https:\/\/flcube.com\/?p=33041","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-08T13:00:27+00:00","article_modified_time":"2025-05-08T13:00:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33041#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33041"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing","datePublished":"2025-05-08T13:00:27+00:00","dateModified":"2025-05-08T13:00:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33041"},"wordCount":176,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33041#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","keywords":["Biotech","Cell-therapy","Finance","Regen Therapeutics","Regenverse Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33041#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33041","url":"https:\/\/flcube.com\/?p=33041","name":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33041#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33041#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","datePublished":"2025-05-08T13:00:27+00:00","dateModified":"2025-05-08T13:00:28+00:00","description":"China-based Guangzhou Regen Therapeutics Co., Ltd, a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson's disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33041#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33041"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33041#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","width":1080,"height":608,"caption":"Guangzhou Regen Therapeutics Raises RMB 100 Million in Pre-Series A Financing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33041#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0802-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33041"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33041\/revisions"}],"predecessor-version":[{"id":33045,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33041\/revisions\/33045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33044"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}